1.Sacher AG, Gandhi L: Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol 2016, 2(9):1217-1222.
2.Keenan TE, Burke KP, Van Allen EM: Genomic correlates of response to immune checkpoint blockade. Nat Med 2019, 25(3):389-402.
3.Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A et al: Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 2018, 50(9):1271-1281.
4.Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002; 110: 673–87.
5.Guan JL. Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer. IUBMB Life. 2010;62: 268–76.
6.Parsons JT. Focal adhesion kinase: the fifirst ten years. J Cell Sci. 2003; 116: 1409–16.
7.Ward KK, Tancioni I, Lawson C, et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis. 2013;30(5):579-594.
8.S.K. Hanks, M.B. Calalb, M.C. Harper, S.K. Patel, Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin, Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 8487–8491.
9.M.D. Schaller, C.A. Borgman, B.S. Cobb, R.R. Vines, A.B. Reynolds, J.T. Parsons, pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions, Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 5192–5196.
10.T.M. Weiner, E.T. Liu, R.J. Craven, W.G. Cance, Expression of focal adhesion kinase gene and invasive cancer, Lancet 342 (1993) 1024–1025.
11.Lark AL, Livasy CA, Calvo B, et al. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res. 2003;9(1):215-222.
12.Judson PL, He X, Cance WG, Van Le L. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer. 1999;86(8):1551-1556.
13.Miyazaki T, Kato H, Nakajima M, et al. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer. 2003;89(1):140-145.
14.Itoh S, Maeda T, Shimada M, et al. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res. 2004;10(8):2812-2817.
15.Sood AK, Armaiz-Pena GN, Halder J, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010;120(5):1515-1523.
16.Golubovskaya VM. Targeting FAK in human cancer: from finding to first clinical trials.Front Biosci (Landmark Ed). 2014;19:687-706.
17.Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications.Nat Rev Cancer. 2014;14 (9): 598-610.
18.Popow J, Arnhof H, Bader G, et al. Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions. J Med Chem. 2019;62(5):2508-2520.
19.Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell. (2012) 21:309–22.
20.Zheng X, Hu Y, Yao C. The paradoxical role of tumor-infiltrating immune cells in lung cancer. Intractable Rare Dis Res. (2017) 6:234–41.
21.Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of antitumor immunity. Cell. 2015; 163:160– 73.
22.Kasorn A, Alcaide P, Jia Y, Subramanian KK, Sarraj B, Li Y, et al. Focal adhesion kinase regulates pathogen-killing capability and life span of neutrophils via mediating both adhesion-dependent and -independent cellular signals. J Immunol. 2009; 183:1032–43.
23.Mitra SK, Lim ST, Chi A, Schlaepfer DD. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene. 2006; 25:4429–40.
24.Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011; 10:2135–45.
25.Batista S, Maniati E, Reynolds LE, Tavora B, Lees DM, Fernandez I, et al. Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis. Nat Commun. 2014; 5:5054. 26.
26.Abshire MY, Thomas KS, Owen KA, Bouton AH. Macrophage motility requires distinct alpha5beta1/FAK and alpha4beta1/paxillin signaling events. J Leukoc Biol. 2011; 89:251–257.
27.Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A): A68-A77.
28.Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. Tgfb Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. Nature (2018) 554(7693):544–48.
29.Neavin DR, Lee J-H, Liu D, Ye Z, Li H, Wang L, et al. Single Nucleotide Polymorphisms at a Distance From Aryl Hydrocarbon Receptor (AHR) Binding Sites Influence AHR Ligand-Dependent Gene Expression. Drug Metab Dispos (2019) 47(9):983–94.
30.Yoshihara K, Shahmoradgoli M, Martı nez E, Vegesna R, Kim H, Torres- ́ Garcia W, et al. Inferring Tumour Purity and Stromal and Immune Cell Admixture From Expression Data. Nat Commun (2013) 4:2612.
31.Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust Enumeration of Cell Subsets From Tissue Expression Profifiles. Nat Methods (2015) 12(5):453–57.
32.Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol (2017) 1:1–15.
33.Canel M, Secades P, Rodrigo JP, et al. Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res. 2006;12(11 Pt 1):3272-3279.
34.Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology. 2003;38(5):1242-1249.
35.Rodrigo JP, Álvarez-Alija G, Menéndez ST, et al. Cortactin and focal adhesion kinase as predictors of cancer risk in patients with laryngeal premalignancy. Cancer Prev Res (Phila). 2011;4(8):1333-1341.
36.Ilic D, Kovacic B, McDonagh S, et al. Focal adhesion kinase is required for blood vessel morphogenesis. Circ Res. 2003;92(3):300-307.
37.Lim ST, Chen XL, Tomar A, Miller NL, Yoo J, Schlaepfer DD. Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motilitypolarity but not cell proliferation. J Biol Chem. 2010; 285:21526–36.
38.Lim ST, Miller NL, Chen XL, Tancioni I, Walsh CT, Lawson C, Uryu S, Weis SM, Cheresh DA, Schlaepfer DD. 2012. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. The Journal of Cell Biology 197:907–919.
39.Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG. 2016. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nature Medicine 22:851–860.
40.Serrels B, McGivern N, Canel M, Byron A, Johnson SC, McSorley HJ, Quinn N, Taggart D, Von Kreigsheim A, Anderton SM, Serrels A, Frame MC. 2017. IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks. Science Signaling 10:eaan8355.
41.K. B. Dunn, M. Heffler, and V. M. Golubovskaya, “Evolving therapies and FAK inhibitors for the treatment of cancer,” Anti Cancer Agents in Medicinal Chemistry, vol. 10, no. 10, pp. 722– 734, 2010.
42.Tai YL, Chen LC, Shen TL. Emerging roles of focal adhesion kinase in cancer. Biomed Res Int. 2015;2015:690.
43.Golubovskaya VM, Zheng M, Zhang L, Li JL, Cance WG. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAKCD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer. 2009;9:280.
44.R. Noy and J.W. Pollard, “Tumor-associated macrophages: from mechanisms to therapy,” Immunity, vol. 41, no. 1, pp. 49–61, 2014.
45.Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. (2012).
46.Atreya I, Neurath MF. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther. (2008) 8:561–72.
47.Zuo S, Wei M, Wang S, Dong J, Wei J. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma. Front Immunol. 2020;11:1218.
48.Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. Ann Oncol (2019) 30(1):44–56.
49.Yamamoto H, Imai K. An Updated Review of Microsatellite Instability in the Era of Next-Generation Sequencing and Precision Medicine. Semin Oncol 2019,46(3):261–70.